Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL938 Combined With Trastuzumab in HER2-positive Metastatic Colorectal Cancer
NCT06589830Phase 2Recruiting
- Sponsor
- SuZhou Teligene
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tl938 in colorectal cancer (CRC), sponsored by SuZhou Teligene. Started May 2025; status: recruiting.
02
Drugs
tl938
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06589830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589830.